04:50:54 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-09-19 Kvartalsrapport 2024-Q2
2024-06-10 Ordinarie utdelning EXTX 0.00 NOK
2024-06-07 Årsstämma 2024
2024-04-18 Bokslutskommuniké 2023
2023-09-28 Kvartalsrapport 2023-Q2
2023-06-12 Ordinarie utdelning EXTX 0.00 NOK
2023-06-09 Årsstämma 2023
2023-04-21 Bokslutskommuniké 2022
2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.
2023-01-04 09:20:53
OSLO, 4 January 2023: The following primary insiders and close associates of
primary insiders of EXACT Therapeutics AS ("Exact-Tx AS") have on January 3,
2023 purchased shares as follows:

- Kvåle AS, a close associate of Chief Operating Officer Svein Kvåle, has
purchased 2,500 shares at NOK 12 per share. Following the purchase, Kvåle AS
holds 3,024,270 shares in Exact-Tx AS

- PAACS Invest AS, a close associate of Board Member Masha Strømme, has
purchased 2,500 shares at NOK 12 per share. Following the purchase, PAACS Invest
AS holds 2,691,509 shares in Exact-Tx AS

- Anders Wold, Chairman of the Board, has purchased 2,500 shares at NOK 12 per
share. Following the purchase, Wold holds 4,914 shares in Exact-Tx AS

- Per Walday, Chief Executive Officer, has purchased 2,500 shares at NOK 12 per
share. Following the purchase, Walday holds 2,500 shares in Exact-Tx AS and
rights to 610,643 shares.

- Amir Snapir, Chief Medical Officer, has purchased 2,500 shares at NOK 12 per
share. Following the purchase, Snapir holds 2,500 shares in Exact-Tx AS and
rights to 60,000 shares

- John M. Edminson, Chief Financial Officer, has purchased 2,500 shares at NOK
12 per share. Following the purchase, Edminson holds 2,500 shares in Exact-Tx AS
and rights to 30,000 shares

This information is subject to the disclosure requirements in Regulation EU
596/2014 (MAR) article 19 number 3 and section 5-12 of the Norwegian Securities
Trading Act.

Primary insider notifications pursuant to the EU Market Abuse Regulation Article
19 are attached hereto.

For more information, please contact:

Per Walday, CEO, per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a Norwegian clinical-stage precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drugtargeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
www.exact-tx.com